The Laser Vision Correction Center of New Jersey (LVCCNJ), Whippany, is the first practice in New Jersey to offer the Valeda® Light Delivery System, an FDA-approved treatment for dry age-related macular degeneration (AMD).
Dry AMD is a leading cause of vision loss among individuals over 50, affecting the macula, the part of the eye responsible for sharp central vision. The disease can cause blurred or fuzzy vision, difficulty adapting to low light, distorted lines, and even permanent blindness. Until now, treatment options were limited to dietary supplements and lifestyle modifications, offering little hope of improving vision.
As the first and only FDA-approved therapy to show vision improvement in clinical trials, Valeda is a non-invasive, light-based treatment that stimulates retinal cell function, helping to slow disease progression, preserve vision, and even enhance sight in some patients.
Valeda delivers precise wavelengths of light into the eye, stimulating cellular energy production and promoting retinal health. The treatment involves three sessions per week for three weeks, repeated up to three times a year. Each session lasts just a few minutes per eye, making it a convenient option for patients.
“This is a game-changer for our patients,” said Dr. Kenneth Miller, director of LVCCNJ. “For the first time, we can go beyond just managing dry AMD—we can actually help improve vision. We’re thrilled to be the first in New Jersey to bring this innovative treatment to our community.”